MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 11, 2006; DOI: 10.1124/mol.106.026070


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.106.026070v1
mol.106.026070v2
70/6/2015    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Artigas, P.
Right arrow Articles by Andersen, O. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Artigas, P.
Right arrow Articles by Andersen, O. S.


Received for publication May 2, 2006.
Revised August 14, 2006.
Accepted for publication September 8, 2006.

2,3 Butanedione Monoxime Affects CFTR Channel Function Through Phosphorylation-Dependent and Phosphorylation-Independent Mechanisms. The role of bilayer material properties

Pablo Artigas 1*, Subhi J. Al'Aref 2, E. Ashley Hobart 3, Lain F. Diaz 4, Masayuki Sakaguchi 5, Samuel Straw 6, Olaf S. Andersen 2

1 Rockefeller University 2 Cornell University 3 Cornell University, 4 Universidad de Chile 5 The Rockefeller University 6 Laboratory of Cardiac/Membrane Physiology, The Rockefeller University

* Address correspondence to: E-mail: artigas{at}rockefeller.edu

Abstract

2,3-butanedione monoxime (BDM) is widely believed to act as a chemical phosphatase. We therefore examined BDM's effects on the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel, which is regulated by phosphorylation in a complex manner. In guinea pig ventricular myocytes, forskolin-activated whole-cell CFTR currents responded biphasically to external 20 mM BDM: a rapid ~2-fold current activation was followed by a slower ({tau} ~20 s) inhibition (to ~20 % of control). The inhibitory response was abolished by intracellular dialysis with the phosphatase inhibitor microcystin, suggesting involvement of endogenous phosphatases. The BDM-induced activation was studied further in Xenopus oocytes expressing human epithelial CFTR. The concentration for half-maximal BDM activation (K0.5) was statedependent, ~2 mM for highly and ~20 mM for partially phosphorylated channels, suggesting a modulated receptor mechanism. Because BDM modulates many different membrane proteins with similar K0.5s, we tested whether BDM could alter protein function by altering lipid bilayer properties rather than by direct BDM-protein interactions. Using gramicidin channels of different lengths (different channel-bilayer hydrophobic mismatch) as reporters of bilayer stiffness, we found that BDM increases channel appearance rates and lifetimes (reduces bilayer stiffness). At 20 mM BDM, the appearance rates increase ~4 fold (for the longer, 15 residues/monomer, channels) to ~10 fold (for the shorter, 13 residues/monomer, channels); the lifetimes increase ~50% independent of channel length. BDM thus reduces the energetic cost of bilayer deformation, an effect that may underlie BDM's effects on CFTR and other membrane proteins; the state-dependent changes in K0.5 are consistent with such a bilayer-mediated mechanism.


Key words: Ion channel regulation, Ion transporters (SERCA, Na/K ATPase, CFTR)





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics